In the news
May 9, 2023
Neuroimmune Interactions: From Basic Mechanisms to Novel Therapeutic Directions
May 8, 2023
Cognito Therapeutics Announces Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting
Apr 27, 2023
epocrates and Cognito Therapeutics Join Forces to Deliver Video Messaging to Healthcare Professionals
Apr 17, 2023
Cognito Therapeutics Announces Key Medical and Technology Leadership Appointments as Late-Stage Neurotechnology Platform Advances
Apr 17, 2023
Cognito finds new medical, technology heads in BrainStorm, Philips alums
Apr 30, 2023
Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer’s Disease at AD/PD 2023
Mar 23, 2023
Neuro Startup Cognito Corrals $73M as Alzheimer’s Device Commences Key Test
Mar 22, 2023
Can light reset brainwaves to treat Alzheimer’s? This Boston startup has $73 million to find out.
Mar 22, 2023
Cognito beams up $73M for study of light-and-sound neuromod therapy to treat Alzheimer's
Mar 22, 2023
Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease
Feb 21, 2023
Cognito Therapeutics Announces First Patient Enrollment in US Pivotal Study HOPE
Jan 20, 2023
The promising new Alzheimer's drugs to watch — and the far-out ideas that could reshape how we treat the disease
Dec 1, 2022
Startup’s Headset to Treat Alzheimer’s Will Undergo Wide Trial With Patients
Nov 1, 2022
Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer’s Disease at 2022 CTAD Conference
Aug 3, 2022
Cognito's light-and-sound therapy slows brain tissue atrophy in Alzheimer's study
Aug 1, 2022
Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients
Jul 13, 2022
Cognito Therapeutics Announces Data Presentations at the Alzheimer’s Association International Conference 2022
May 9, 2022
Cognito Therapeutics Joins Digital Medicine Society’s (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Clinical Measures
May 2, 2022
Some health apps are able not just to diagnose diseases, but also to treat them
Apr 13, 2022
Gamma Sensory Stimulation Demonstrates Efficacy in Alzheimer Disease in New Analysis
Mar 31, 2022
With pharma still struggling in Alzheimer’s, health tech companies want a swing
Mar 14, 2022
Ushering in a New Class of Disease-Modifying DTx
Mar 11, 2022
Cognito Therapeutics, Aetion to partner on AI model that identifies AD patients
Mar 8, 2022
Cognito Therapeutics and Aetion Announce Partnership to Use Artificial Intelligence to Identify Rapidly Progressing Forms of Mild Cognitive Impairment and Alzheimer's Disease
Mar 7, 2022
Fierce Medtech Names Cognito Therapeutics as One of Its “Fierce 15” Med Tech Companies of 2021
Mar 7, 2022
Fierce Medtech's 2021 Fierce 15
Mar 3, 2022
Cognito Therapeutics Announces Presentations for Novel Therapeutic in Alzheimer’s Disease at the 2022 American Academy of Neurology (AAN) Conference
Mar 1, 2022
Cognito Therapeutics to Present Virtual Symposium “Predicting Alzheimer’s Disease Progression with Neurophysiological Markers” at 2022 AD/PD Conference
Jan 27, 2022
Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment
Dec 14, 2021
Cognito Therapeutics Appoints Jennifer Newberger as Head of Regulatory and Compliance
Dec 8, 2021
Digital Therapeutics Alliance Elects Cognito Therapeutics’ Everett Crosland to its Board of Directors
Sep 15, 2021
Cognito Therapeutics CEO Brent Vaughan to Speak at CODE Conference 2021
Sep 8, 2021
Cognito Therapeutics Announces Formation of Payor Advisory Board
Aug 4, 2021
Cognito Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2021
Jul 26, 2021
Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021
Jul 14, 2021
Cognito Therapeutics Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2021
Jul 6, 2021
Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board
Jun 14, 2021
Cognito Therapeutics Initiates Studies in Down Syndrome Associated Alzheimer’s Disease
May 18, 2021
Cognito Therapeutics Appoints Everett Crosland as Chief Commercial Officer
May 5, 2021
Cognito Therapeutics Appoints Jonathan Lieber as Chief Financial Officer
Mar 17, 2021
Cognito Therapeutics to Advance Digital Therapeutic for Alzheimer’s into Pivotal Studies Based on Positive Clinical Results Announced at AD/PD 2021
Mar 9, 2021
Cognito Therapeutics Announces Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer’s Disease
Mar 2, 2021
Cognito Therapeutics to Announce New Clinical Data Evaluating Gamma Frequency Neuromodulation to Treat Alzheimer’s Disease at 2021 AD/PD Virtual Conference
Jan 27, 2021
Cognito Therapeutics Appoints Mark Day, Ph.D., as Chief Business Officer
Jan 12, 2021
Cognito Therapeutics Receives FDA Breakthrough Device Designation for Next-Generation Digital Therapeutic in Alzheimer’s Disease
Dec 19, 2020